- Home
- DXLG vs CCEL Comparison
DXLG vs CCEL Comparison
Compare DXLG & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXLG | CCEL |
|---|---|---|
| Founded | 1976 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Managed Health Care |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 32.7M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DXLG | CCEL |
|---|---|---|
| Price | $0.54 | $3.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 114.7K | 12.5K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.45% |
| EPS Growth | N/A | ★ 104.39 |
| EPS | N/A | ★ 0.17 |
| Revenue | ★ $467,015,000.00 | $25,384,279.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | $3.24 | N/A |
| P/E Ratio | ★ N/A | $19.82 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.52 | $3.10 |
| 52 Week High | $2.35 | $7.91 |
Technical Indicators
Market Signals| Indicator | DXLG | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 36.05 | 49.35 |
| Support Level | $0.52 | $3.33 |
| Resistance Level | $0.99 | $3.57 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 13.14 | 68.87 |
Price Performance
Historical ComparisonAbout DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.